Faron Pharmaceuticals hits bump in road for Traumakine manufacturing
2nd Oct 2019 14:57
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced on Wednesday that, further to its update in its interim results in relation to the active pharmaceutical ingredient (API) manufacturing process for 'Traumakine', Rentschler Biopharma has sent Faron a letter in which it terminated the agreement concerning the API manufacturing.
Read moreFaron Pharma raises ?2.3m to keep it going through the start of 2020
27th Aug 2019 16:34
(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals has received valid acceptances and excess applications from qualifying shareholders for a total of 859,513 open offer shares, raising gross proceeds of around €1.01m (£0.92m) at the issue price of 106p per share and at the euro issue price of 119 cents per share, it announced on Tuesday.
Read moreFaron Pharmaceuticals reports 'significant' findings from YODA study
14th Jun 2019 10:37
(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced results from its pharmacokinetic/dynamic 'YODA' study examining the administration of concomitant steroids and Traumakine in healthy volunteers on Friday.
Read moreFaron appoints new CFO after some internal shuffling
24th May 2019 11:50
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals updated the market on its board and management team on Friday, announcing that Yrjö Wichmann was leaving his current role as its chief financial officer to take up the new position of vice-president, financing and investor relations.
Read moreFaron Pharmaceuticals upbeat on latest info from MATINS trial
11th Apr 2019 11:22
(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced on Thursday that the cohort expansion part of its phase 1 and 2 'MATINS' clinical trial, investigating the safety and efficacy of its wholly-owned novel precision cancer immunotherapy 'Clevegen', would begin with patients suffering from late-stage colorectal cancer as soon as the optimal dosing was determined.
Read moreFaron Pharmaceuticals shares surge on latest Clevegen data
21st Feb 2019 10:09
(Sharecast News) - Shares in Faron Pharmaceuticals were surging on Thursday morning, after it announced an update on early observations on immunity and clinical response of MATINS patients after administration of its 'Clevegen' product.
Read moreFaron Pharmaceuticals pins some hope to YODA trial
19th Dec 2018 11:07
(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals issued interim results from its pharmacokinetic/dynamic 'YODA' study on Wednesday, examining various formulations of recombinant human interferon-beta (IFN-beta).
Read moreDosing begins in Faron's study of 'Clevegen' drug
14th Dec 2018 15:57
(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced on Friday that the first patient has successfully been dosed in the phase I/II MATINS study of Clevegen, its wholly-owned novel precision cancer immunotherapy drug.
Read moreTraumakine treatment optimal for particular subgroup, Faron finds
5th Dec 2018 10:13
(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals has identified, by genetic testing, an "optimal subgroup" of acute respiratory distress syndrome (ARDS) patients for Traumakine treatment who showed a substantial reduction in mortality during the INTEREST trial, it announced on Wednesday.
Read moreFaron Pharmaceuticals applies to begin Clevegen clinical trials
3rd Dec 2018 10:09
(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced on Monday that its clinical trial application to conduct a Phase I/II study with 'Clevegen', its wholly-owned novel precision cancer immunotherapy drug in development for the treatment of selected metastatic or inoperable tumours, has been approved by the Finnish Medicines Agency (FIMEA).
Read moreFaron losses widen following disappointing Traumakine trial
13th Sep 2018 08:36
(Sharecast News) - Faron Pharmaceuticals' operating loss doubled in the first half of its trading year following the group's disappointing trial on its Traumakine treatment.
Read moreFaron Pharmaceuticals makes solid progress with drug programmes
9th Feb 2017 08:20
(ShareCast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals updated the market on Thursday, ahead of its full year 2016 audited financial results which its board said will be announced on 29 March. The AIM-traded firm said for its Traumakine project, it expects to obtain the re
Read moreFaron Pharma granted protection for IFN-beta by Finnish patent office
31st Oct 2016 12:44
(ShareCast News) - Faron Pharmaceuticals' patent application to protect the intravenous use of interferon-beta, a cytokine protein, in a novel formulation has been accepted by the Finnish patent office that enables the company to build a global proprietary position for its Traumakine drug. The claim
Read moreFaron Pharma raises £8m to fund R&D
21st Sep 2016 15:13
(ShareCast News) - AIM listed Faron Pharmaceuticals raised £8m through a share placing and subscription to fund safety trials, pre-clinical advances and various research and development operations in biopharmaceuticals. The Finland-based company raised £8m through a placing of about 2.86m shares and
Read more